New discovery of Anticancer Monomer-Ganoderma Lucidum Extract GL22

Researchers believe that the uncontrolled rapid growth of cancer cells requires a large number of substances, including nucleic acids, fatty acids and amino acids. Cancer cells alter metabolism to meet increased demand for bioenergy and biosynthesis. The reorganization of lipid metabolism pathway is one of the significant changes in cancer cells. A new monomer, triterpenoid compound GL22, was extracted from Ganoderma lucidum in Linzhi area, Tibet (the structure is as follows).

Role of GL22

GL22 could inhibit the activity of HMG-CoA reductase and alpha-glucosidase in vitro, and showed toxicity to K562 and PC-3 cancer cell lines. Researchers say this is the first discovery of fungal secondary metabolites that stimulate antitumor activity by targeting FABPs and depleting cardiac fat.

GL22 characteristics

Experiments have proved that GL22 treatment can inhibit the expression of FABPs, effectively inhibit the growth of hepatocellular carcinoma in vitro and in vivo, leading to loss of cardiolipin, mitochondrial dysfunction and cell death.